Pediatric Cancers

Children with acute lymphocytic leukemia and their parents commonly over-report the amount of daily oral chemotherapy the child takes to treat the most common blood cancer in children.

Genetic variants increase the risk of osteonecrosis in children under age 10 with acute lymphoblastic leukemia.

Researchers have identified a genetic variant, 2R thymidylate synthase polymorphism, that is associated with an increased risk for avascular necrosis in children with ALL.

Targeted MAPK-pathway inhibitor therapies appear to have reduced tumor sizes in four children’s inoperable astrocytomas-tumors that had progressed despite chemotherapy.

PEG-asparaginase had both similar safety and efficacy to intramuscular native E coli l-asparaginase for the treatment of children with ALL in complete remission.

In this review, childhood cancer survivor populations at risk for metabolic late effects, as well as mechanisms and ongoing intervention studies, will be detailed.

It is too soon to determine the influence of radiation exposure on thyroid cancer risk among children and adolescents exposed to the 2011 Fukushima Daiichi nuclear power plant disaster in Japan, according to the lead author of findings presented at the 85th Annual Meeting of the ATA.

A new study has found an excess of thyroid cancer cases among children and adolescents who live near the Fukushima Daiichi nuclear power plant.

Risk for leukemia was significantly lower among children in Taiwan who were infected with the enterovirus compared with children who were not infected.

Even in the absence of cranial radiation therapy, survivors of childhood acute lymphoblastic leukemia (ALL) have decreased neurocognitive function years later.

According to the AREN0532 and AREN0533 trials, adding additional drugs to a therapy regimen for Wilms tumor in children with high-risk disease improved outcomes.

A revised International Pediatric Non-Hodgkin Lymphoma Staging System (IPNHLSS) could allow for more precise staging for children and adolescents with NHL.

Stem cell transplantation from an HLA-genoidentical sibling or an HLA-matched unrelated donor did not affect outcomes among high-risk pediatric ALL patients.

The US Food and Drug Administration has approved dinutuximab (Unituxin) for the treatment of high-risk neuroblastoma in pediatric patients.

Researchers have identified two genetic characteristics that may distinguish pediatric secondary high-grade glioma from primary high-grade glioma.

Using genome-wide association studies, researchers have identified a germline variant that is associated with intolerance to mercaptopurine in pediatric ALL.

In a recent study of pediatric ALL, minimal residual disease was able to predict patients who were at increased risk for relapse post-allogeneic stem cell transplantation.

A large trial has shown that adolescents and young adults have better event-free and overall survival when treated on an intensive pediatric ALL regimen.

In this video from the 2014 ASH Meeting, Dr. Grupp discusses data from a trial using CAR T-cell therapy in children and young adults with relapsed, treatment-resistant ALL.

T-lymphoblastic leukemia (T-ALL) should no longer be considered a poor-risk disease in the pediatric population, according to data presented at ASH.

Monitoring minimal residual disease and real-time quantitative polymerase chain reaction can predict relapse in pediatric acute lymphoblastic leukemia patients.

Results of a new study show that cancer rates among children and adolescents are stable, but rates of certain cancers such as renal carcinomas are increasing.

Long-term outcomes of patients treated for pediatric acute lymphoblastic leukemia (ALL) with modern treatment protocols are good, with an overall low risk for serious long-term side effects.

Researchers have identified Down syndrome as a risk factor for infection-related mortality among pediatric patients with acute lymphoblastic leukemia.

A new risk-stratification system for pediatric and young adult patients with non-rhabdomyosarcoma soft-tissue sarcomas (NRSTS) was able to effectively classify patients for the appropriate therapy.

High-dose chemotherapy plus conventional radiotherapy resulted in a high 3-year overall survival in children and adolescents with newly diagnosed medulloblastoma and supratentorial primitive neuroectodermal tumor.

Obesity or underweight status at diagnosis can influence outcomes in pediatric ALL patients, but a new study shows that the risk can be mitigated if weight status changes following treatment induction.

Contrary to some previous research as well as popular belief, living underneath or near to power lines as a child may not have any notable effect on childhood leukemia risk, according to a new case-control study conducted in the United Kingdom.

Treatment with gemtuzumab ozogamicin improved the event-free survival in children and adolescents with acute myeloid leukemia by reducing the risk of relapse among those able to achieve remission, according to trial results presented at the 2013 ASH meeting.

Adult survivors of pediatric acute lymphoblastic leukemia (ALL) suffer from persistent and significant neurocognitive deficits, according to a new study.